Evidence map›Paper›PMID 33836840›Full record

ArticleImplementation science communications2021

Mixed-methods economic evaluation of the implementation of tobacco treatment programs in National Cancer Institute-designated cancer centers.

Ramzi G Salloum, Heather D'Angelo, Ryan P Theis, Betsy Rolland, Sarah Hohl, Danielle Pauk, Jennifer H LeLaurin, Yasmin Asvat, Li-Shiun Chen, Andrew T Day and 17 more

Abstract read
In one paragraph

Article in Implementation science communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Impact of tobacco smoking on disease-specific outcomes in common neurological disorders: A scoping review.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Ramzi G SalloumDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA. rsalloum@ufl.edu.ORCID http://orcid.org/0000-0002-8139-2418
Heather D'AngeloUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Ryan P TheisDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA.
Betsy RollandUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Sarah HohlUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Danielle PaukUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Jennifer H LeLaurinDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA.
Yasmin AsvatRush University Medical Center and Rush Cancer Center, Chicago, IL, USA.
Li-Shiun ChenWashington University Siteman Cancer Center, St Louis, MO, USA.
Andrew T DayUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Adam O GoldsteinUniversity of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.
Brian HitsmanNorthwestern University Feinberg School of Medicine and Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Deborah HudsonIndiana University Simon Cancer Center, Indianapolis, IN, USA.
Andrea C KingUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Cho Y LamHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Katie LenhoffDartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon, NH, USA.
Arnold H LevinsonUniversity of Colorado Comprehensive Cancer Center, Aurora, CO, USA.
Judith ProchaskaStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Fabrice SmieliauskasBarbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
Kathryn TaylorGeorgetown University Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Janet ThomasUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
Hilary TindleVanderbilt University Medical Center Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Elisa TongUniversity of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Justin S WhitePhilip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA.
W Bruce VogelDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, 2004 Mowry Road, Gainesville, FL, USA.
Graham W WarrenMedical University of South Carolina Hollings Cancer Center, Charleston, SC, USA.
Michael FioreUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
NCATS NIH HHS UL1 TR002538NCI NIH HHS 17GZSK0031NCI NIH HHS P30 CA091842
6 · The paper itself

Abstract

backgroundThe Cancer Center Cessation Initiative (C3I) was launched in 2017 as a part of the NCI Cancer Moonshot program to assist NCI-designated cancer centers in developing tobacco treatment programs for oncology patients. Participating centers have implemented varied evidence-based programs that fit their institutional resources and needs, offering a wide range of services including in-person and telephone-based counseling, point of care, interactive voice response systems, referral to the quitline, text- and web-based services, and medications.

methodsWe used a mixed methods comparative case study design to evaluate system-level implementation costs across 15 C3I-funded cancer centers that reported for at least one 6-month period between July 2018 and June 2020. We analyzed operating costs by resource category (e.g., personnel, medications) concurrently with transcripts from semi-structured key-informant interviews conducted during site visits. Personnel salary costs were estimated using Bureau of Labor Statistics wage data adjusted for area and occupation, and non-wage benefits. Qualitative findings provided additional information on intangible resources and contextual factors related to implementation costs.

resultsMedian total monthly operating costs across funded centers were $11,045 (range: $5129-$20,751). The largest median operating cost category was personnel ($10,307; range: $4122-$19,794), with the highest personnel costs attributable to the provision of in-person program services. Monthly (non-zero) cost ranges for other categories were medications ($17-$573), materials ($6-$435), training ($96-$516), technology ($171-$2759), and equipment ($10-$620). Median cost-per-participant was $466 (range: $70-$2093) and cost-per-quit was $2688 (range: $330-$9628), with sites offering different combinations of program components, ranging from individually-delivered in-person counseling only to one program that offered all components. Site interviews provided context for understanding variations in program components and their cost implications.

conclusionsAmong most centers that have progressed in tobacco treatment program implementation, cost-per-quit was modest relative to other prevention interventions. Although select centers have achieved similar average costs by offering program components of various levels of intensity, they have varied widely in program reach and effectiveness. Evaluating implementation costs of such programs alongside reach and effectiveness is necessary to provide decision makers in oncology settings with the important additional information needed to optimize resource allocation when establishing tobacco treatment programs.

Indexed as

Economic evaluationImplementation costsMixed methodsSmoking cessationTobacco treatment

Identifiers

PMID33836840
PMCPMC8033545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.